{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T02:57:04Z","timestamp":1781492224141,"version":"3.54.1"},"reference-count":107,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2020,11,15]],"date-time":"2020-11-15T00:00:00Z","timestamp":1605398400000},"content-version":"vor","delay-in-days":14,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Over the last decade, chimeric antigen receptor (CAR)\u2010T cell therapy has emerged as a promising treatment modality for relapsed\/refractory B\u2010cell malignancies in both children and adults. As an adoptive immune therapy, CAR\u2010T cells have the potential to overcome disease that is resistant to chemo\u2010 and radiotherapy as well as represent a viable option for those who have already reached toxicity ceilings with standard therapies. CD19\u2010directed CAR\u2010T cell products have been licensed for use in paediatric B\u2010cell acute lymphoblastic leukaemia that is refractory, in relapse post\u2010transplant or in second or later relapse. Many challenges remain, rightly resulting in a heavily\u2010mined research field. These include mitigating short\u2010term immune\u2010mediated toxicity, maintaining durability of responses, broadening treatment accessibility and extending its applicability to other malignant settings. In this review, dedicated to marking 60\u00a0years since the establishment of the British Society for Haematology, we will focus on the contribution of our community towards the success of CD19\u2010directed CAR\u2010T cell therapy in children. We will put current practice in CAR\u2010T cell therapy into the context of future challenges to be addressed in order for it to fulfil its \u201cgame\u2010changing\u201d therapeutic potential.<\/jats:p>","DOI":"10.1111\/bjh.17153","type":"journal-article","created":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T01:19:19Z","timestamp":1693876759000},"page":"617-626","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["CAR\u2010T cell therapy in paediatric acute lymphoblastic leukaemia \u2013 past, present and future"],"prefix":"10.1111","volume":"191","author":[{"given":"Srdan","family":"Rogosic","sequence":"first","affiliation":[{"name":"Developmental Biology and Cancer Great Ormond Street Institute of Child Health University College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Ghorashian","sequence":"additional","affiliation":[{"name":"Developmental Biology and Cancer Great Ormond Street Institute of Child Health University College London London UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2020,11,15]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-108-6-806"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1097\/00062752-199811000-00016"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0301-472X(99)00096-X"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2010.07.001"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199002013220507"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197905103001902"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V75.3.555.555"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcmd.2007.07.003"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.smim.2018.01.002"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1423-0410.1998.tb05463.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1517\/14712590902967588"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20040613"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198812223192527"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1097\/00002371-200307000-00005"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2249.2009.03912.x"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-03-211714"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-01-0146"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibtech.2007.05.001"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.90.2.720"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.167.11.6123"},{"issue":"5","key":"e_1_2_7_22_1","first-page":"1976","article-title":"T\u2010cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor\u2010mediated T\u2010cell proliferation but does not affect receptor\u2010mediated target cell lysis","volume":"61","author":"Hombach A","year":"2001","journal-title":"Cancer Res"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.161.6.2791"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.172.1.104"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/nbt0102-70"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2403302"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.83"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0813101106"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-04-1041"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2005.04.016"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.210"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-117737"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2015.09.004"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm827"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-07-0674"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-07-1989"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.0901440"},{"key":"e_1_2_7_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-04-281931"},{"key":"e_1_2_7_39_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2010.38"},{"key":"e_1_2_7_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2010.03.014"},{"key":"e_1_2_7_41_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46110"},{"key":"e_1_2_7_42_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215134"},{"key":"e_1_2_7_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1407222"},{"key":"e_1_2_7_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"e_1_2_7_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-02-769208"},{"key":"e_1_2_7_46_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709866"},{"key":"e_1_2_7_47_1","unstructured":"Kymriah [Highlights of prescribing information].East Hanover (NJ):Novartis Pharmaceuticals Corporation;2017. Available from:https:\/\/www.fda.gov\/files\/vaccines%2C%20blood%20%26%20biologics\/published\/Package\u2010Insert\u2010\u2010\u2010KYMRIAH.pdf"},{"key":"e_1_2_7_48_1","unstructured":"BoseleyS.NHS to treat young cancer patients with expensive \u201cgame changer\u201d drug. The Guardian[newspaper on the Internet].2018Sep 5 [cited 2020 October 8]. Available from:https:\/\/www.theguardian.com\/society\/2018\/sep\/05\/nhs\u2010treat\u2010young\u2010cancer\u2010patients\u2010expensive\u2010game\u2010changer\u2010drug\u2010kymriah"},{"key":"e_1_2_7_49_1","doi-asserted-by":"publisher","DOI":"10.1097\/HS9.0000000000000186"},{"key":"e_1_2_7_50_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.2520"},{"key":"e_1_2_7_51_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000692"},{"key":"e_1_2_7_52_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI85309"},{"key":"e_1_2_7_53_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa063842"},{"key":"e_1_2_7_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_7_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-04-348540"},{"key":"e_1_2_7_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-08-519413"},{"key":"e_1_2_7_57_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3008226"},{"key":"e_1_2_7_58_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-05-552729"},{"key":"e_1_2_7_59_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005930"},{"key":"e_1_2_7_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.15644"},{"key":"e_1_2_7_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0036-4"},{"key":"e_1_2_7_62_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000241"},{"key":"e_1_2_7_63_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019003821"},{"key":"e_1_2_7_64_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707447"},{"key":"e_1_2_7_65_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41409-019-0451-2"},{"key":"e_1_2_7_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123424"},{"key":"e_1_2_7_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-01-694356"},{"key":"e_1_2_7_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.148"},{"key":"e_1_2_7_69_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-04-703751"},{"key":"e_1_2_7_70_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-07-793760"},{"key":"e_1_2_7_71_1","doi-asserted-by":"publisher","DOI":"10.2478\/ahp-2020-0004"},{"key":"e_1_2_7_72_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa121"},{"key":"e_1_2_7_73_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy152"},{"key":"e_1_2_7_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-019-0083-5"},{"key":"e_1_2_7_75_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910607"},{"key":"e_1_2_7_76_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI125423"},{"key":"e_1_2_7_77_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25582"},{"key":"e_1_2_7_78_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0442"},{"key":"e_1_2_7_79_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018025726"},{"key":"e_1_2_7_80_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129411"},{"key":"e_1_2_7_81_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113714"},{"key":"e_1_2_7_82_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-113126"},{"key":"e_1_2_7_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017011254"},{"key":"e_1_2_7_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature22395"},{"key":"e_1_2_7_85_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00262-018-2155-7"},{"key":"e_1_2_7_86_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-683847"},{"key":"e_1_2_7_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-019-0297-y"},{"key":"e_1_2_7_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3838"},{"key":"e_1_2_7_89_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI133215"},{"key":"e_1_2_7_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0290-5"},{"key":"e_1_2_7_91_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0549-5"},{"key":"e_1_2_7_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-131086"},{"key":"e_1_2_7_93_1","unstructured":"Autolus Therapeutics.Autolus Therapeutics Announces FDA Acceptance of IND Application for AUTO1 for Adult Acute Lymphoblastic Leukemia. Press Release.2020. Available from:https:\/\/autolus.gcs\u2010web.com\/news\u2010releases\/news\u2010release\u2010details\/autolus\u2010therapeutics\u2010announces\u2010fda\u2010acceptance\u2010ind\u2010application."},{"key":"e_1_2_7_94_1","unstructured":"FurnessC HoughR CumminsM MurphyG GhorashianS AmroliaP et al.National Implementation of the use of tisagenlecleucel in paediatric and adult population with acute lymphoblastic leukaemia (ALL) in National Health Service England (NHSE). In: 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT).2020. Available from:https:\/\/www.professionalabstracts.com\/ebmt2020\/iPlanner\/#\/presentation\/5006"},{"key":"e_1_2_7_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/mto.2016.15"},{"key":"e_1_2_7_96_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1752592"},{"key":"e_1_2_7_97_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-129640"},{"key":"e_1_2_7_98_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaj2013"},{"key":"e_1_2_7_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-019-13007-6"},{"key":"e_1_2_7_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-99-112544"},{"key":"e_1_2_7_101_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.5_2632"},{"key":"e_1_2_7_102_1","unstructured":"Minard\u2010ColinV MaudeV BuechnerJ KruegerJ LocatelliF AttarbaschiA et al.BIANCA: Phase 2 Single\u2010arm global trial to determine efficacy and safety of tisagenlecleucel in paediatric\/young adult patients with relapsed\/refractory B\u2010cell Non\u2010Hodgkin lymphoma. In: EHA Library.2020. p.293737; EP1248. Available from:https:\/\/library.ehaweb.org\/eha\/2020\/eha25th\/293737\/."},{"key":"e_1_2_7_103_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0801-y"},{"key":"e_1_2_7_104_1","doi-asserted-by":"publisher","DOI":"10.21037\/tcr.2016.06.04"},{"key":"e_1_2_7_105_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.208751"},{"key":"e_1_2_7_106_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00326"},{"key":"e_1_2_7_107_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-11-629071"},{"key":"e_1_2_7_108_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-07-652057"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.17153","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,5]],"date-time":"2023-09-05T01:20:10Z","timestamp":1693876810000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.17153"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":107,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1111\/bjh.17153"],"URL":"https:\/\/doi.org\/10.1111\/bjh.17153","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"2020-11-15","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}